Department of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):373-375. doi: 10.1093/jpids/piaa052.
Children with perinatally acquired human immunodeficiency virus (PHIV) face a lifetime of combination antiretroviral treatment that often includes dolutegravir (DTG). DTG, an integrase strand inhibitor that has been linked to weight gain in adults, is increasingly being used in children. Understanding its potential short- and long-term sequelae in children is critically important. We report a case of excessive weight gain in a child with PHIV on DTG and provide a brief literature review.
儿童感染人类免疫缺陷病毒（PHIV）后，需要终身接受联合抗逆转录病毒治疗，其中常包含多替拉韦（DTG）。DTG 是一种整合酶链转移抑制剂，在成人中与体重增加有关，在儿童中越来越多地被使用。了解其在儿童中的潜在短期和长期后果至关重要。我们报告了一例 PHIV 儿童在使用 DTG 治疗后体重过度增加的病例，并进行了简要的文献复习。
